Scott Paulson
Scott Paulson publishes mostly in Oncology, Epidemiology and Pulmonary and Respiratory Medicine, on topics such as Neuroendocrine Tumor Research Advances, Lung Cancer Research Studies and Gastric Cancer Management and Outcomes.
- World rank
- #3,275,469 of 7,710,434 ranked researchers
- Rank in United States
- #927,028 of 1,627,098
- Works
- 23
- Citations
- 379
- Citations per work
- 16.5
What does Scott Paulson research?
Scott Paulson's work is mostly in Medicine (68%), Biochemistry, Genetics and Molecular Biology (5%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences1667.7%
- Medicine1667.7%
- Everything else627.5%
- Life Sciences14.8%
- 1Oncology27% of their works
- 2Epidemiology14% of their works
- 3Pulmonary and Respiratory Medicine13% of their works
- 4Surgery8% of their works
- 5Neurology5% of their works
- 6Molecular Biology5% of their works
Research topics
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Gastric Cancer Management and Outcomes
- Neuroblastoma Research and Treatments
- Colorectal Cancer Treatments and Studies
- Fibroblast Growth Factor Research
- Gastrointestinal Tumor Research and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
Which keywords describe Scott Paulson's research?
The keywords of their largest research topics: Chemotherapy, Survival Analysis, Genetic Mutations, Immunotherapy, Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumors, Prognostic Factors and Clinical Practice Guidelines.
- Liver Cancer
- Hepatocellular Carcinoma
- FGF21
- KRAS Mutations
- ALK
- Gastric Cancer
- Small-Cell Lung Cancer
- Clinical Practice Guidelines
- Pancreatic Neuroendocrine Tumors
- Immunotherapy
- Survival Analysis
- Chemotherapy
- Genetic Mutations
- Neuroendocrine Tumors
- Prognostic Factors
- Genomic Profiles
- Endoscopic Resection
- Therapy
- Cetuximab
- Neuroblastoma
- Fibroblast Growth Factor
- Imatinib Mesylate
- Sunitinib
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 23 words, with their numbers
- Chemotherapy143 topics
- Survival Analysis132 topics
- Genetic Mutations112 topics
- Immunotherapy92 topics
- Neuroendocrine Tumors81 topic
- Pancreatic Neuroendocrine Tumors81 topic
- Prognostic Factors82 topics
- Clinical Practice Guidelines72 topics
- Genomic Profiles61 topic
- Small-Cell Lung Cancer61 topic
- Endoscopic Resection51 topic
- Gastric Cancer51 topic
- Therapy52 topics
- ALK31 topic
- Cetuximab31 topic
- KRAS Mutations31 topic
- Neuroblastoma31 topic
- FGF2121 topic
- Fibroblast Growth Factor21 topic
- Hepatocellular Carcinoma21 topic
- Imatinib Mesylate21 topic
- Liver Cancer21 topic
- Sunitinib21 topic
Where does Scott Paulson work?
Scott Paulson's main affiliation in the publication record is Texas Oncology, United States.
How many publications and citations does Scott Paulson have?
OpenAlex counts 23 works and 379 citations for Scott Paulson, an h-index of 8, ranking #3,275,469 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Other researchers named Scott Paulson
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Scott Paulson. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.